and edrophonium tests. According to Estacio, treatment for myasthenia gravis involves careful use of anticholinesterase and ...

Heightened focus on delays in diagnosing generalized myasthenia gravis (gMG) follows the promise of better results for some patients with newer treatments that include complement inhibitors and ...

Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.

Welcome, everyone. I'm Dr. John Whyte, the Chief Medical Officer at WebMD. Today, I want to discuss myasthenia gravis. It's a rare autoimmune neuromuscular disease that causes weakness and fatigue ...

Myasthenia gravis patients show higher rates of dysarthria, dysphonia, dysphagia, and aspiration pneumonia compared to non-affected individuals. Despite high disorder rates, most myasthenia gravis ...

Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half of 2025. Click here to read more.

Treatment with inebilizumab was associated with continued improvement in patients with acetylcholine receptor autoantibody-positive (AChR+) generalized myasthenia gravis (gMG), according to 52-week ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Myasthenia Gravis is a long-term, autoimmune condition in which the communication between muscles and nerves is impaired due to the production of certain antibodies resulting in voluntary muscle ...

The Neuromuscular Disease Center has a long history of providing excellent clinical care and research in myasthenia gravis. Myasthenia gravis is a chronic autoimmune disorder that causes muscle ...

Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Generalized myasthenia gravis (gMG) affects most patients ...